Short Interest in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Increases By 209.8%

Key Points

• Short interest in Nanobiotix S.A. has surged by 209.8%, increasing from 6,100 shares to 18,900 shares as of July 31st, resulting in a short-interest ratio of 2.4 days.
• On July 31st, Nanobiotix's stock price fell 3.5% to $7.91, while its 52-week range has been between $2.76 and $8.47.
• Institutional investors now own 38.81% of Nanobiotix's stock, with recent stakes purchased by Geode Capital Management, Millennium Management, and Jane Street Group, valued at approximately $29,000, $39,000, and $73,000, respectively.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - ) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 18,900 shares, anincreaseof209.8% from the July 15th total of 6,100 shares. Based on an average trading volume of 7,900 shares, the short-interest ratio is presently 2.4 days. Approximately0.0% of the shares of the stock are short sold. Approximately0.0% of the shares of the stock are short sold. Based on an average trading volume of 7,900 shares, the short-interest ratio is presently 2.4 days.

Nanobiotix Stock Down 3.5%

NASDAQ NBTX traded down $0.29 during trading hours on Friday, hitting $7.91. 10,127 shares of the company's stock traded hands, compared to its average volume of 10,188. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $8.47. The firm's 50-day moving average is $5.70 and its 200-day moving average is $4.32.

Institutional Trading of Nanobiotix

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $29,000. Millennium Management LLC purchased a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $39,000. Finally, Jane Street Group LLC purchased a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $73,000. Hedge funds and other institutional investors own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.